This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers 2023;9. https://doi.org/10.1038/s41572-023-00438-1.
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N. Engl J Med. 2023;388:2338–48.
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38:1156–63.
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147–59.
Newell LF, Holtan SG. Acute GVHD: think before you treat. Hematol Am Soc Hematol Educ Program. 2021;2021:642–7.
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N. Engl J Med. 2013;369:529–39.
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, et al. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Blood. 2024;144:1010–21.
Srinagesh HK, Ferrara JLM. MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application. Best Pract Res Clin Haematol. 2019;32. https://doi.org/10.1016/j.beha.2019.101111.
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3:4034–42.
Robin M, Porcher R, Michonneau D, Taurines L, de Fontbrune FS, Xhaard A, et al. Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. Blood Adv. 2022;6:4763–72.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4–10.
Author information
Authors and Affiliations
Contributions
AC, FC, MTLS and AR, designed the research, AC collected the data, JEG and AR analyzed the data, AC, and AR wrote the manuscript; MCA, LL, ED, AB, SP, DC, SM, LV, RG, FF, AC, DS, AA, GMB, SM, CC, MB, AA, were in charge of patients and provided critical review of the manuscript. Data are available upon request to the corresponding author.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Criscimanna, A., Galimard, J.E., Auriemma, M.C. et al. Validation of Manhattan risk to predict aGvHD severity in Rapamycin and PTCy-based prophylaxis: a study on 459 consecutive HCT patients. Bone Marrow Transplant 60, 1394–1397 (2025). https://doi.org/10.1038/s41409-025-02677-0
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41409-025-02677-0
